Streetwise Reports' Article Archives — November 2020 back to current month (28)
Novavax shares traded 11% higher after the company finalized enrollment in two advanced COVID-19 vaccine clinical trials with a third one slated to commence in the coming weeks.
Shares of Rhythm Pharmaceuticals traded 25% higher after the FDA granted approval of IMCIVREEÖ (setmelanotide) as the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency.
Algernon Pharmaceuticals reported it has enrolled 154 patients in its Phase 2b/3 human study of Ifenprodil for COVID-19 and is increasing the pool to 168 patients to allow for attrition.
Preclinical results for Black Diamond Therapeutics' kinase inhibitor, BDTX-1535, are reviewed in an H.C. Wainwright & Co. report.
The design of Apellis Pharmaceuticals and its partner's clinical study is presented in a ROTH Capital Partners report.
Shares of Renalytix AI Plc. traded 30% higher after the company reported Q1/21 financial results and that its joint venture with Mt. Sinai Health System was granted Emergency Use Authorization by the FDA for its SARS-CoV-2 IgG antibody test kit.
Revive Therapeutics enters an agreement with PharmaTher, a specialty psychedelics pharmaceutical firm.
Precision BioSciences shares traded 13% higher after the company reported it is partnering with Eli Lilly & Co. to develop in vivo therapies for genetic disorders with an initial focus on Duchenne's muscular dystrophy and two other undisclosed gene targets.
Shares of Corcept Therapeutics reached a new 52-week high after the firm reported that the U.S. Patent Trial and Appeals Board affirmed that all claims pertaining to its U.S. Patent No.10,195,214 are valid.
Kodiak Sciences shares reached a new 52-week high after the company announced the pricing of a $560.9 million public offering of its common stock. The report came one day after the firm advised it had completed enrollment of its Phase 2b/3 Pivotal DAZZLE Study of KSI-301 in patients with wet age-related macular degeneration.
Shares of Lexicon Pharmaceuticals traded higher after the company published results from the Phase 3 SOLOIST and SCORED trials showing that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits.
Delic Corp., a thought leader in psychedelics, will trade on the Canadian Securities Exchange.
Moderna shares traded 10% higher to a new 52-week high after the company reported its COVID-19 vaccine candidate, mRNA-1273, met its primary endpoint in the first interim analysis of the Phase 3 COVE Study by achieving an efficacy rate of 94.5%.
Revive Therapeutics reported that it has developed an oral thin-film strip psilocybin product with doses ranging from 1 to 20 milligrams.
Shares of Urovant Sciences traded 93% higher to a new 52-week high after the company reported that it entered into a definitive agreement to be acquired by Sumitovant Biopharma for $16.25 per share in cash.
ProMIS Neurosciences formed two new joint ventures, one for developing tests for the detection, diagnosis and monitoring of Alzheimer's disease, and the second for serological assays for antibodies to the SARS-CoV-2 virus.
ProMIS Neurosciences, which is developing its own therapeutics for this disease, weighs in on the committee's conclusions regarding Biogen's aducanumab.
Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020.
Paratek Pharmaceuticals' recent and future revenue are discussed in an H.C. Wainwright & Co. report.
Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer.
Independent financial analyst Matt Badiali profiles a digital therapeutics company that is changing diabetes treatment.
Pfizer shares traded 9% higher to a new 52-week high after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection. The company is making plans to produce up to 1.3 billion vaccine doses in 2021.
Knox Henderson delves into how Draganfly's cutting-edge technology is making it possible for universities and other organizations to operate safely during the pandemic.
Shares of Glaukos Corp. traded 9% higher after the company reported Q3/20 financial results that included an 11% YoY increase in glaucoma and corneal health net sales.
ImmunoGen's broad pipeline that "could support long-term growth" is discussed in an H.C. Wainwright & Co. report.
Shares of Supernus Pharmaceuticals traded higher after the company reported financial results for Q3/20 that included a 52% increase in total revenues versus the same period in 2019.
Shares of Inspire Medical Systems traded 30% higher and set a new 52-week high after the company reported Q3/20 financial results that included a 72% rise in YoY revenue.
Two doses of Algernon Pharmaceuticals' NP-120, or Ifenprodil, are being tested for safety and efficacy.
|"Momentum continues to build for VIV."|